U.S.-Made Peptides Gain Ground as Quality Concerns Rise in Booming Market

MIAMI — As the global market for therapeutic peptides and GLP-1 agonists surges into a multibillion-dollar industry, a growing number of American clinics and physicians are turning to domestic manufacturers, citing stricter quality controls and regulatory oversight.

Alpha Biologix, a Miami-based company, has positioned itself as a key player in this shift, emphasizing 100 percent United States manufacturing at a time when cheaper imports, particularly from China, are raising alarms among health professionals.

The worldwide market for therapeutic peptides exceeded $140 billion in 2025 and is projected to approach $300 billion by 2033. In the United States, demand has been propelled by rising interest in weight management, metabolic health, tissue repair and longevity treatments.

In an interview at the company’s headquarters in Miami, Lucas Torres, Director of Expansion at Alpha Biologix, described the current landscape as both promising and perilous.

“The peptides market is growing exponentially, but unfortunately so is the flood of low-quality products coming from Asia,” Mr. Torres said. “At Alpha Biologix we made a deliberate choice from day one: everything is manufactured here in the United States under strict regulatory standards. This allows us to deliver a level of purity and consistency that simply cannot be guaranteed with the Chinese copies saturating the market.”

Mr. Torres emphasized that the company’s clients — primarily clinics and medical professionals — are seeking more than just price.

“Our customers want peace of mind,” he said. “They know that by choosing products made in the USA they are getting full supply chain traceability, independent third-party testing and compliance with American regulations. We don’t just sell peptides. We sell trust and predictable clinical outcomes.”

Alpha Biologix produces a range of research-grade peptides, including BPC-157, CJC-1295, Ipamorelin and AOD-9604, as well as GLP-1 formulations such as semaglutide, tirzepatide and retatrutide. All are manufactured domestically under current Good Manufacturing Practices (cGMP).

Industry experts note that while the peptide sector offers significant therapeutic potential, the proliferation of unregulated imports has created a two-tier market: one defined by rigorous standards and another by cost-cutting and minimal oversight.